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Abstract 27 
There is a growing need for low-cost, rapid and reliable diagnostic results in veterinary medicine. Point-of-28 
care (POC) tests have tremendous advantages over existing laboratory-based tests, due to their intrinsic 29 
low-cost and rapidity. A considerable number of POC tests are presently available, mostly in dipstick or 30 
lateral flow formats, allowing cost-effective and decentralised diagnosis of a wide range of infectious 31 
diseases and public health related threats. Although, extremely useful, these tests come with some 32 
limitations. Recent advances in the field of microfluidics have brought about new and exciting opportunities 33 
for human health diagnostics, and there is now great potential for these new technologies to be applied in 34 
the field of veterinary diagnostics. This review appraises currently available POC tests in veterinary 35 
medicine, taking into consideration their usefulness and limitations, whilst exploring possible applications 36 
for new and emerging technologies, in order to widen and improve the range of POC tests available. 37 
Keywords 38 
Point-of-care, veterinary diagnostics, microfluidics, lateral flow immunoassays, paper-based microfluidics, 39 
dipstick test. 40 
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1. Introduction 50 
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 51 
Point-of-care (POC) diagnostics is an area that has attracted considerable attention in the last decade. 52 
Testing at POC means that analytical procedures are carried out at the side of or near to the patient [1], for 53 
this reason, it is also sometimes referred to as “bed-side” testing [2]. The reasons for the considerable 54 
interest in the field of POC testing are numerous: the potential to decrease costs of diagnosis [3], increasing 55 
the accessibility of these types of test to disadvantaged populations [4], and reducing the time between 56 
sampling and a treatment decision [5]. 57 
Following the global trend towards more affordable and accessible diagnostic testing, the Sexually 58 
Transmitted Diseases Diagnostics Initiative (SDI) within the World Health Organization (WHO) recently 59 
established a set of benchmark criteria for the ideal rapid test, under the acronym “ASSURED” [6]:  60 
Affordable, Sensitive, Specific, User-friendly (simple to perform in a few steps, with minimal technical 61 
training), Robust and rapid (results available in less than 30 min), Equipment-free, Deliverable to those who 62 
need them. Ideally, POC tests should respect all or as many as possible of these characteristics [7]. 63 
 64 
2. Point of care testing and its scope in veterinary medicine 65 
 66 
In the veterinary area, there is a similar need for low-cost, reliable and rapid diagnostic tests to be 67 
carried out at the POC [8]. So called on-site or animal-side tests will have considerable advantages over 68 
laboratory-based testing, which usually involves laborious and expensive laboratory techniques and 69 
dedicated technical personnel. All of the analytical processes involved in testing, from collection of the 70 
sample to communication of the results, could potentially be performed in a single step, considerably 71 
reducing the time between testing and treatment [9]. This can translate into more affordable veterinary 72 
care, reduced handling of animals, targeted treatments and rapid testing in more remote geographic areas.  73 
The need for more affordable, rapid and accessible tests is a recurrent theme in the literature, in 74 
particular as an invaluable tool in dealing with diseases that either represent a threat to public health [10], 75 
have substantial impact on animal welfare [11] and/or are of economic importance [12], with particular 76 
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relevance to situations where laboratory facilities and funds are limited [13]. Furthermore, the general 77 
globalisation of trade of animals and animal products has greatly increased the risk of rapid and wide-78 
ranging spread of emerging and exotic diseases, requiring timely and efficient ways of dealing with diseases 79 
that could have catastrophic repercussions for the individual farmer, as well as economic implications for 80 
the entire country and international trade [14]. In situations concerning disease outbreaks, where rapid 81 
propagation of infectious agents and/or high mortality are salient features, as in the case of the highly 82 
pathogenic H5N1 strain of avian influenza virus, a rapid “animal-side” test would represent a critical tool 83 
for both collecting surveillance data and for assisting in the control of outbreaks [11, 15]. Currently 84 
available veterinary POC tests offer a good opportunity for a truly “animal-side” diagnosis, but the 85 
analytical performances of “on-site” testing are still considered limited compared with laboratory-based 86 
testing [16], whilst the possibility offered by the support of a central laboratory in the interpretation of the 87 
results is still perceived as critical [17]. Recent advances in microfluidic technologies for POC testing in the 88 
human field could overcome these hurdles and might be applied in veterinary medicine. This review aims 89 
to appraise the current status of POC testing in veterinary medicine, describing their advantages and 90 
limitations, whilst also assessing the potential of microfluidic technologies to improve existing POC tests 91 
and solve some of their intrinsic limitations. 92 
 93 
3. Point-of-care devices currently available in veterinary diagnostics 94 
 95 
At present, the most widely used technologies for POC testing in veterinary medicine are: dipstick tests 96 
and lateral flow immunoassays. 97 
 98 
3.1 Dipstick and strip test 99 
 100 
These assays are based on the principle of immunoblotting and are made of paper strips with pads to 101 
analyse specific fluids. After the sample is introduced, the results are compared with a colour-coded chart 102 
to provide a semi-quantitative determination of the analyte(s). The most commonly used are test strips 103 
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developed for human urine analysis, allowing the simultaneous detection or monitoring of leukocytes, 104 
nitrite, urobilinogen, protein, pH, haemoglobin, specific gravity, ketones, bilirubin and/or glucose (Fig. 1) 105 
[18].  While it has been developed for human patients, there is a high correlation between the dipstick 106 
results and other routinely used methods for urine analysis, which has resulted in this test being widely 107 
used in small animal private practice for first-line diagnosis of chronic kidney disease, mainly through an 108 
assessment of proteinuria [19, 20]. However, care should be taken when interpreting positive test results 109 
with low levels of proteins (traces) due to the high rate of false positive results [21]. 110 
A smaller version of the urine dipstick, restricted to detection of glucose and ketone bodies, is also 111 
largely applied for at-home management of pets with diabetes. This test is also widely used in farmed 112 
ruminants for the diagnosis of ketosis in cattle [22] and pregnancy toxaemia in sheep. Due to some 113 
variation in results, a further advance in the diagnosis of these diseases is the use of appropriate strips 114 
combined with electronic hand-held meters to accurately measure both glucose and one of the main 115 
ketone bodies, ß- bhydroxybutyrate (BHB) in blood, making diagnosis more reliable as well as sampling 116 
potentially more successful and less stressful [23]. This POC test has shown great potential for the 117 
quantitative detection of BHB, with improved sensitivity and specificity when compared with dipstick tests 118 
for detection of ketones in urine or milk [24, 25]. Its use for glucose measurement, however, does not seem 119 
to be reliable [23]. Dipstick tests have also been used for the detection of antibiotics in serum, milk and/or 120 
meat samples [26]. These rapid tests allow the detection of antibiotics within the µg/ml range, permitting 121 
on-site monitoring of non-authorised uses of antimicrobials, which could be especially useful in 122 
slaughterhouses and food processing plants.   123 
The main advantage of these POC tests is that they can be readily carried out by the owners, proving to 124 
be particularly useful for the long term management of chronic diseases [27]. The major limitation, 125 
however, can be the subjective interpretation of results, based on a personal evaluation of a colorimetric 126 
reaction [19]. 127 
 128 
3.2 Lateral flow immunoassays (LFIAs) 129 
 130 
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These devices are based on the principle of capillary force: a liquid flowing on or through a strip of 131 
polymeric material, on or in which specific molecules (e.g., antigens, antibodies, DNA/RNA sequence) have 132 
been immobilized [28]. These strips usually consist of multiple pads: a sample application pad, a conjugate 133 
pad, a membrane for detection and an absorbent pad (Fig. 2), usually made of different materials (e.g., 134 
nitrocellulose, glass fibre paper and fused silica) encased in a plastic cage for protection of a fragile paper 135 
membrane [29]. The best known example of a lateral flow test is the pregnancy test [30], which is probably 136 
the most used POC test worldwide. The main advantages of lateral flow over traditional laboratory-based 137 
tests are their simplicity, rapidity and low cost. Compared with traditional laboratory-based tests, LFIAs are 138 
considerably less expensive, but, due to the different materials required, they are still relatively costly (~ 139 
$10 for a pregnancy test; [29]) for application in low-resource settings [31], and, due to the multi step 140 
processes involved, manufacturing time is extended, making them less suitable for high-throughput 141 
production. 142 
They usually provide a qualitative or semi-quantitative result, and analytical performance is generally 143 
poorer than laboratory-based tests, mainly due to reduced sensitivity [32, 33] and the possibility of errors 144 
due to testing by untrained personnel [2]. When compared with reference laboratory tests, specificity 145 
tends to be comparable, while sensitivity can be as low as 16%, suggesting that a positive result might be 146 
trusted, whereas, in the case of negative results, further confirmatory laboratory testing may be advisable. 147 
Several studies have assessed quantitation, but such devices still require instrumentation [34, 35] and 148 
trained personnel, and are still limited to single analyte testing. 149 
 150 
3.2.1 Companion animals 151 
 152 
There is a significant market for the use of LFIAs for a range of acute and chronic diseases or conditions 153 
in companion animals (Table 1). These assays are usually easy to perform and interpret [32], with the 154 
possibility to improve sensitivity by using a dedicated LFIA reader, which allows an objective and 155 
quantitative interpretation of the results [28]. Although the cost of the test is an important consideration, 156 
reduced waiting time and the possibility of starting a therapy within the first visit are amongst the main 157 
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advantages of tests that can be carried out “in-house”. It is also important to consider that some diseases 158 
have received considerably greater attention, notably viral infection diseases, such as FIV and FeLV in cats 159 
and parvovirus in dogs, with an extended range of assays being available.  160 
 161 
3.2.2 Livestock 162 
 163 
For livestock, LFIAs have been focused mainly on illnesses that represent a substantial economic burden 164 
and/or serious zoonotic or epidemic diseases (Table 2). OIE-listed diseases of the World Organization for 165 
Animal Health, such as Foot-and-Mouth Disease (FMD) and Rinderpest have received considerable 166 
attention, due to the crucial importance of a rapid diagnosis and, consequently, prompt intervention from 167 
veterinary authorities. In the case of FMD, endemic areas are frequently in developing countries, and often 168 
diagnosis is not reached due to the prolonged time between collection of samples, arrival at the reference 169 
laboratory and subsequent testing [36]. In this case, both the economic constraints and accessibility to 170 
remote areas are the dominant issues. 171 
 172 
3.2.3 Food safety 173 
 174 
Lateral flow tests have been successfully applied in two main areas: the detection of food-borne 175 
pathogens and the detection of fraudulent substances in animal feed or in animal products (Table 3). In the 176 
first case, much emphasis is placed on the prevention of zoonotic diseases, which represent a significant 177 
and widespread public health threat. In the second case, recent feed-stuff scandals [37, 38] and increasing 178 
reports of antimicrobial resistance dominate the scene, both in terms of research and public attention. 179 
Here, and on-site test can be a powerful tool for rapid detection and subsequent surveillance, especially 180 
when dealing with highly perishable products. 181 
 182 
4. Microfluidic technologies available for POC diagnostics 183 
 184 
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One of the most promising technologies that has been applied recently in diagnostics is microfluidics, 185 
which involves the analysis of extremely small amounts (microlitres or nanolitres) of fluid using 186 
interconnected networks of channels measuring tens to hundreds of micrometres [39]. Since the 187 
introduction of microfluidics from the early 1990s [40], there has been a constant evolution of these 188 
methods, mainly following critical advances in microfabrication technologies [41]. Fluid transport in these 189 
devices is achieved by either passive (usually capillary forces) or active (generally pumping) mechanisms 190 
[42, 43], with the fluid flow being typically laminar [44]. 191 
Among the main advantages of microfluidics technologies for diagnostic applications are their 192 
portability and their low consumption of reagents; these attributes have made these devices inexpensive, 193 
rapid and generally easier to use compared with conventional (macroscale) testing [45]. The use of very 194 
small volumes, associated with shorter diffusional distances, results in significantly reduced time for 195 
analysis, making microfluidic assays significantly more rapid to perform than their macroscale equivalents 196 
[46]. Furthermore, being able to perform all necessary steps within one device and potentially in a single 197 
reaction represent a considerable advantage, allowing sample pre-treatment, analysis, signal detection and 198 
amplification in the same device [47]. Automated control of all steps can reduce inherent human error, 199 
which in turn increases the quality, reproducibility and reliability of assay results. The higher degree of 200 
control of fluid flow and the timing of binding reactions can also result in significantly improved analytical 201 
performance [48], while the opportunity for tests to be carried out simultaneously offers considerable 202 
potential for multiplexing [47]. Examples of the successful applications of these new technologies are in the 203 
clinical analysis of blood [49-51], pathogen identification [52, 53], genetic testing [54, 55], detection of 204 
environmental contaminants [56] and for drug screening [57]. 205 
Currently, two main types of microfluidic systems are used in the diagnostic field: micro total analysis 206 
systems (µTAS) and microfluidic paper-based analytical devices (µPADs). However, to date, there has been 207 
very limited application of this technology in the veterinary field [58]. 208 
 209 
4.1 Micro total analysis systems (µTAS) 210 
 211 
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These systems are also commonly known as “lab on a chip” (LOC) devices (Fig. 3), which use fluid as a 212 
working medium and can integrate a number of different functionalities on a micro scale [41]. One of the 213 
main advantages of µTAS devices is that they allow for all steps (from sample pre-treatment to signal 214 
detection) to be carried out at once, on the same device, allowing complicated molecular techniques (i.e. 215 
polymerase chain reaction (PCR)) to be transferred on the chip for POC testing. These devices are 216 
fabricated using techniques from the microelectronics industry [59], mostly using materials, such as silicon, 217 
glass and/or polymers [60]. At present, the most common materials used are thermoplastic polymers. 218 
These devices have reduced production costs, and have suitable mechanical, chemical and thermal 219 
properties [61]. 220 
Their diagnostic use is well established, with companies already commercialising POC devices on plastic 221 
platforms [62]. In the last decade, there has been a considerable focus on immunodiagnostic tests for the 222 
detection of disease markers, specifically for cardiac and cancer markers [63-66] and for the diagnosis of 223 
infectious diseases, including HIV/AIDS [67, 68], influenza [69] and hepatitis [70]. Some limitations of these 224 
devices are inherent in physical effects, such as the need for pressure-driven liquid flow, with the possible 225 
consequence of heat generation and, therefore, detrimental effects on biomolecules, or low grade mass 226 
transfer and/or reduced mixing capacity [41]. 227 
 228 
4.2 Microfluidic paper-based analytical devices (µPADs) 229 
 230 
These devices are commonly referred to as paper-based microfluidics (Fig. 4), a concept that was first 231 
introduced by the Whiteside group at Harvard University, following on from initial research performed on 232 
paper strips for the determination of pH [71]. These devices allow inexpensive multiplexed analyses to be 233 
carried out [72], while maintaining the advantages of conventional microfluidic technology, such as size, 234 
speed and reduced sample volumes [7]. Paper has considerable advantages over other materials in that it is 235 
cheap, easy to source, biodegradable and naturally abundant, but also simple to modify chemically [73]. 236 
POC devices made from paper also have the advantage of not requiring external power sources, whilst 237 
fabrication techniques and machinery for production are usually less expensive than those for other 238 
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materials, with minimal technical expertise required [74]. Paper represents an excellent medium for 239 
diagnostic testing, due to its high surface to volume ratio, which allows reagents to be concentrated, 240 
enabling more rapid reaction times [75]. Although µTAS are renowned for being less expensive than 241 
conventional laboratory-based testing, materials such as glass and silicon can still be considered expensive, 242 
either in terms of their environmental footprint or in their production costs [47]. Therefore, one of the 243 
main advantages of choosing µPADs over µTAS as a diagnostic platform is their reduced cost. Also µPADs 244 
are considered to be “easier” to produce, with no requirement for valves or pumps, as they use capillary 245 
force to move fluids within the device [74]; however, there can be issues with sample retention and 246 
evaporation, making them less suited to the analysis of small volumes [76]. 247 
 248 
5. Possible applications of microfluidic technologies in veterinary medicine  249 
 250 
POC is already widely applied in veterinary medicine, and new and emerging technologies could bring 251 
substantial improvements to both the range of tests available and their inherent performance. The 252 
reduction in cost and time coupled to the possibility of multiplexing and one-step applications make these 253 
devices attractive for cost-effective and on-site testing of animals. Although microfluidics are, at the 254 
moment, predominantly applied to human diagnostics (Table 4), there have been examples of applications 255 
to areas of veterinary interest [77-81]. Microfluidic platforms have been successfully used for detection of 256 
food-borne pathogens, such as Escherichia coli O157:H7, Listeria monocytogenes and Salmonella 257 
typhimurium [82] as well as for detection of progesterone in serum samples [83]. The use of microfluidics 258 
has also been applied to improve the range of existing POC tests available for the detection of subclinical 259 
ketosis in cattle [84], in particular, by allowing on farm testing of samples such as milk. 260 
 261 
5.1 Nucleic acid amplification 262 
 263 
Combining nucleic acid amplification techniques with microfluidic technologies to detect low 264 
concentrations of molecules in a rapid, reliable and economical way represents an opportunity for new POC 265 
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technologies. The most widely used amplification technique is PCR [85], which is often used for infectious 266 
disease diagnosis, especially for the detection of small amounts of pathogen DNA. A possible limitation of 267 
laboratory-based PCR techniques is their cost, and the time and expertise required for testing. A promising 268 
application of microfluidics  is DNA amplification on silicon chips [86], although the need for a thermocycler 269 
limits its application in the field. For this reason, new amplification technologies, based on isothermal 270 
nucleic acid amplification have received considerable attention, and appear to allow for improvement of 271 
assay sensitivity, while providing a rapid and cost-effective approach [87]. Examples of the integration of 272 
this method into µTAS devices are growing [88-91], with existing applications to the detection of pathogens 273 
of veterinary importance, such as Cryptosporidium parvum [92, 93], E. coli [94], Salmonella typhimurium 274 
[77, 95] and Suid herpesvirus 1 [96]. 275 
 276 
5.2 Multiplexing 277 
 278 
A significant benefit of microfluidic technologies is the possibility to perform different tests in or on the 279 
same device [97]. Multiplexing has particular relevance in situations where multiple agents are involved 280 
[98] or where clinical signs are similar between/among distinct diseases [99, 100]. In this case, a POC 281 
“package” could be offered, in order to screen a single sample for all key pathogens involved in a particular 282 
disease scenario or complex [101, 102]. Other advantages could be the parallel interpretation of different 283 
tests for the same condition, in order to significantly increase test sensitivity [103] and the analysis of 284 
multiple markers to specifically diagnose a disease or condition, especially in the case of a progressive 285 
disease; or for monitoring therapeutic effectiveness. Finally, performing multiple tests at once, can also 286 
result in a reduction in cost, time and sample use [104]. 287 
 288 
5.3 Telemedicine and surveillance 289 
 290 
Perhaps the most important advance in diagnostics is the possibility of combining microfluidics 291 
technologies with mobile read outs and electronic data storage. Since mobile phones have become 292 
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household items across the world and smart-phone cameras are of a high quality [105], the combination of 293 
these technologies could truly represent the future for POC. Examples of mobile read out and telemedicine 294 
applied to microfluidics are increasing [106-109], and show great promise. They allow for remote and cost 295 
efficient diagnosis, and also for information to be stored and shared automatically, making the process 296 
time-efficient and reducing human error [110]. At the same time, animal tracking systems are becoming 297 
automated, with widespread use of electronic identification, in the format of microchips and electronic ear 298 
tags/boluses. From the veterinary perspective, exploiting the opportunities of “distance-diagnosis” with 299 
efficient animal tracking could have a tremendous impact on disease control and surveillance, with 300 
considerable advantages for the monitoring of notifiable and zoonotic diseases, as in the case of bovine 301 
spongiform encephalopathy (BSE) [111] and in screening for changes in disease patterns [112]. Surveillance 302 
schemes are mostly carried out by official laboratories at considerable cost [113]. Recent restructuring of 303 
some diagnostic services will inevitably have a significant impact on diagnostic capability [114], which 304 
means that the present scanning surveillance systems may not be sustainable in the long term, such that 305 
alternative options might be required. 306 
 307 
5.4 Disposal and handling of biological material 308 
 309 
One of the main advantages of microfluidic devices is the possibility for the safe disposal of biological 310 
material [115]. This is of particular relevance for paper, where disposal of bio-hazardous waste could be 311 
safely and quickly achieved by incineration [116]. The advantages are in the further reduction of waste 312 
management costs, but, more importantly in the reduced risks of handling biological samples that might 313 
represent a health and safety risk [117]. It has been shown that veterinary surgeons are often concerned 314 
about the health and safety of packaging samples entering the postal system, as they are responsible for 315 
proper packaging and the safety of the recipient [17]. Therefore, safe and low-cost disposal of potentially 316 
bio-hazardous material represents a substantial added benefit for  these new technologies.   317 
 318 
6. Challenges 319 
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 320 
One of the biggest challenges in the field of microfluidics is the translation from academic research to 321 
end-user products [118]. While the field of microfluidics has seen an exponential development in recent 322 
years, the launch of a commercialised platform that would revolutionise the concept of microfluidic 323 
technologies is still lacking [119]. Something similar to the breakthrough achieved by the pregnancy test 324 
may be required to enable microfluidics-based testing to be more widely accepted. Unfortunately, the fact 325 
that the diagnostic field is already quite mature, makes it harder to find companies willing to invest in new 326 
areas [116], and the difficulties in changing people’s attitudes toward testing can represent an additional 327 
hurdle, especially when methods have been in place for many years. In this respect, the perception that 328 
analytical performances are still inferior to traditional laboratory-based tests remains a considerable 329 
constraint to the uptake of these technologies [2]. However, there is evidence that when a rapid result can 330 
achieve a better treatment rate, the sensitivity of a test can play a less important role [120]. This situation 331 
is extremely applicable in the veterinary field, where owners may struggle to find time for follow up visits 332 
after a test has been performed, or it may be problematic for farmers to re-gather animals days after 333 
testing [121]. Furthermore, as already in place for instrumental veterinary POC testing [122], specific 334 
guidelines should be put in place for the quality assurance of newly developed POCs, in order to provide a 335 
consistent and practical approach to evaluating their performance and increasing veterinarians’ confidence 336 
in test results [123].  337 
While some of the challenges faced in human healthcare have been addressed by the use of microfluidic 338 
technologies, this is not the case for animal health-related areas. For example, although the use of 339 
microfluidic technologies is suited for telemedicine, the handling or recording of data needs to be carefully 340 
organised. Data management systems are available for POC [124], which allow for valuable information to 341 
be stored and made available in real time. However, in the case of notifiable diseases, specific rules and 342 
strict controls will be required to ensure that legislation is followed.  Another significant challenge will be 343 
the need for targeted solutions according to the specific situation, remembering that a beloved sick 344 
companion animal will require a different approach from livestock displaying signs of a potentially zoonotic 345 
disease. 346 
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Finally, in order to fully exploit the potential of the new technologies at the POC, a higher degree of 347 
collaboration between engineers and biologists is required. Whilst, at the moment, the majority of the 348 
publications regarding microfluidics are in engineering journals [125], increasing publication of these topics 349 
in biological journals would help overcome some of the existing barriers. From an engineering point of 350 
view, research may focus predominantly on resolving the physical and chemical barriers posed by 351 
microfluidic technologies, while, from a veterinary diagnostics perspective, practical solutions are the main 352 
focus. By facilitating better communication between technology designers and end-users, a truly 353 
interdisciplinary approach could be achieved, which will help to solve the issue of translation of these 354 
technologies to the veterinary field.  355 
 356 
7. Conclusions 357 
 358 
Considering the wide array of veterinary conditions and the nature of veterinary diagnostics, POC 359 
testing offers distinct advantages over traditional laboratory-based testing. The advent of microfluidic 360 
technologies has further increased the opportunities for wider and more valuable use of POC testing. 361 
Although these technologies have not yet been applied as widely to veterinary medicine as they have in 362 
human medicine, they still offer great potential. Many of the hurdles encountered in diagnostics are 363 
commonly shared in human and animal medicine; advances in one field will therefore provide benefits to 364 
both sides, as long as specific needs faced from an animal health point of view are kept in mind. 365 
Importantly, a close collaboration between engineers, developing new and existing technologies and those 366 
at the end point in need of improved solutions will be of paramount importance.  367 
  368 
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 769 
Figure Legends 770 
Fig. 1. Urine analysis performed using a dipstick test. The test strip is immersed in the urine sample for a 771 
few seconds, and, after a few minutes, the colour resulting from the reaction  can be visually compared 772 
against the chromatic scale provided. 773 
 774 
Fig. 2. Schematic representation of a lateral flow strip. A liquid sample is deposited on to the sample pad, 775 
migrating through a conjugate pad and a porous membrane for detection in a final absorbent pad. In most 776 
strip tests, the appearance of the control line indicates a valid test, while the appearance of a second test 777 
line indicates a positive test result. 778 
 779 
Fig. 3. Stand-alone, self-powered integrated microfluidic blood analysis system (SIMBAS) [51]. The 780 
microfluidic platform integrates plasma separation from whole-blood with multiple immunoassays (A). 781 
Cross section of the device (B): fabrication materials (1); storage of the device in a vacuum package (2); 782 
addition of 5 ml of whole-blood sample on the inlet, degas-driven flow propels the sample into the device 783 
(3); blood cells sediment gravitationally and are filtered, while plasma flows into the channel (4); detection 784 
of multiple biomarkers (5); the flow is stopped by the suction chamber (6). 785 
 786 
Fig. 4. 3D Origami-based microfluidic paper based analytical device [126]. Schematic representation, size 787 
and shape of the 3D origami-based device (A); the front and back surface of the device (B); binding of a 788 
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baked thin wax-patterned blotting paper on each waste tab, front (C) and back (D); binding of an unbaked 789 
thick wax-patterned blotting paper on each waste tab (E, F). The assay procedure is carried out by folding 790 
the different tabs above the test pad and adding the reagents sequentially, with the aid of a customised 791 
device folder. 792 
 793 
  794 
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Table 1. Examples of lateral flow immunoassays for POC diagnosis currently available for companion animals. 
 
 
 
 
 
 
Disease/condition Sample Target analyte/pathogen Target species Commercial name References 
Addison’s and Cushing 
disease 
Serum Cortisol Dogs SNAP® Cortisol Test http://www.idexx.co.uk 
Arthropod-borne diseases Blood, serum or plasma Anaplasma phagocytophilum 
and platys, 
Ehrlichia canis and ewingii, 
Borrelia burgdorferi,  
Leishmania infantum, 
Dirofilaria immitis 
Cats and dogs SNAP® 4Dx® Plus Test 
SNAP® 3Dx® Test 
SNAP Leishmania 
[127, 128] 
Cardiomyopathies Serum or plasma N-terminal pro-brain natriuretic 
peptide (NTproBNP) 
Cats SNAP® Feline proBNP Test [129] 
FIV and FeLV Blood, serum or plasma FIV and FeLV Cats BioSign® FeLV; BioSign® FIV; BioSign® FeLV/FIV; 
EVL One-step test; FASTest FeLV-FIV; 
SNAP® FIV/FeLV Combo Test; SNAP® Feline 
Triple® Test Speed Duo FELV/FIV; Witness FeLV-
FIV 
[130] 
Giardiasis Faeces Giardia Cats and dogs SNAP® Giardia Test 
VetScan® Giardia Rapid Test 
http://www.idexx.co.uk 
Heartworm Blood, serum or plasma Dirofilaria immitis Cats and dogs BioSign® CHW; SNAP Feline Heartworm 
SNAP® Feline Triple® Test; WITNESS® 
DIROFILARIA 
[131] 
Liver disease Serum Bile acid Cats and dogs SNAP® Bile Acids Test [132] 
Lungworm Serum or plasma Angiostrongylus vasorum Dogs Angio Detect™ Test http://www.idexx.co.uk 
Pancreatitis  Serum Pancreas-specific lipase Cats and dogs SNAP® fPL™ Test; SNAP® cPL™ Test [133] 
Parvovirus Faeces Parvovirus Dogs FASTest parvo strip; Witness parvo card; SAS™ 
Parvo; SNAP® Parvo Test; VetScan Canine 
Parvovirus Rapid Test; Speed® Parvo 
[32] 
Passive transfer of immunity Blood, serum or plasma IgG Foals SNAP® Foal IgG Test 
 
http://www.idexx.co.uk 
Thyroid disease Serum or plasma T4 Cats, dogs and 
horses 
SNAP® Total T4 Test 
SNAP® T4 Test 
http://www.idexx.co.uk 
Thromboembolic disease Citrated plasma D-dimer Dogs NycoCard D-dimer test [134] 
Toxoplasmosis Serum Toxoplasma gondii Cats N/A [135] 
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Table 2. Examples of lateral flow immunoassays for POC diagnosis currently available for livestock. 
Disease/condition Sample Target analyte/pathogen Target species Commercial name References 
Anaplasmosis Serum Anaplasma marginale Cattle N/A [136] 
Aujeszky’s Disease (Pseudorabies) Serum Suid herpesvirus type 1 Pigs N/A [137] 
Bovine viral diarrhoea (BVD) Serum and ear notch Bovine viral diarrhoea virus 
(BVDV) 
Cattle SNAP® BVDV Test http://www.idexx.co.uk 
Classical Swine Fever Blood Classical swine fever virus Pigs CSFV Ab Test http://www.idexx.co.uk 
Foot and mouth disease (FMD) Vesicular epithelium 
and fluid, blood 
Foot and mouth disease virus Ruminants and pigs BioSign™ FMDV 
BioSign™ FMDV-Ag 
[36, 138-140] 
Infectious bursal disease Bursa Infectious bursal disease virus Chickens N/A [141] 
Neonatal diarrhoea Faeces Bovine rotavirus Cattle Rainbow Calf Scour Diagnostic Test [33] 
Passive transfer of immunity Serum or plasma IgG Cattle Midland quick test kit-calf IgG [142] 
Peste des petit ruminant Lachrymal fluids Peste des petit ruminant virus Sheep and goats N/A [143] 
Porcine reproductive and 
respiratory syndrome 
Serum Porcine reproductive and 
respiratory syndrome virus 
(PRRSV) 
Pigs BioSign® PRRSV [12] [144] 
Reproductive status Milk Progesterone Cattle N/A [145] 
Rinderpest Lachrymal fluids Rinderpest virus Cattle N/A [146] 
Tuberculosis Blood, serum or 
plasma 
Mycobacterium bovis Red deer, wild boar, 
elephants, cattle and 
non-human primates 
CervidTB STAT-PAK; VetTB STAT-
PAK test; DPP® CervidTB; 
DPP® VetTB Assay for Elephants; 
PrimaTB STAT-PAK 
[147-152] 
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Table 3. Examples of lateral flow immunoassays for POC diagnosis currently available for food safety. 
Disease/condition Sample Target analyte/pathogen Target species Commercial name References 
Acute bloody diarrhoea Milk Escherichia coli O157:H7 Cattle N/A [153] 
Anabolic steroid residues Urine and liver Medroxyprogesterone acetate (MPA) Pigs N/A [154] 
Antibiotic contamination Milk, eggs, meat and 
urine 
Beta-lactam, oxytetracycline, 
(dihydro)streptomycin gentamicin and 
sulfamethazine 
Cattle, pigs, poultry, 
sheep and goats 
Betastar® Combo Rapid Test; BioSign™ 
Sulfamethazine; Charm SL6™ Beta-lactam Test 
SNAP® Beta-Lactam ST Test; SNAPduo™ Beta-
Tetra Test; SNAPduo™ Beta-Tetra Test ST; 
SNAP® Gentamicin Test; SNAP® MRL Test; 
SNAP® NBL Test; SNAP® Tetracycline Test; 
SNAP® Sulphamethazine Test 
[155-160] 
BSE Brain PrPBSE Cattle Prionics-Check PrioSTRIP [161] 
Clenbuterol contamination Urine Clenbuterol Pigs N/A [162] 
Mammalian proteins 
contamination of feed stuff 
Plasma Bovine IgG Cattle N/A [163] 
Melamime Milk Melamime Cattle SNAP® Melamine Test [164] 
Mycotoxins contamination Feed matrix and milk Aflatoxin B1 and M1, deoxynivalenol 
and zearalenone 
Cattle and pigs SNAP® AFM1 Test 
ROSA Mycotoxin Strips 
 
[165, 166] 
Nicarbazin residues Feed matrix Nicarbazin Poultry N/A [167] 
Salmonellosis Meat Salmonella typhimurium and enteritidis Poultry N/A [168] 
Trichinellosis Blood, serum and 
meat 
Trichinella spiralis Pigs N/A [169], [170]  
 
Table 4. Examples of commercially available microfluidic-based POC technologies for human diagnostic applications. 
Diagnostic application Time to results Sample type Technology Commercial name Company homepage 
Blood analysis (blood gas, electrolyte, 
haematology and metabolite panel) 
30 seconds 
2 minutes 
Whole blood (100µl) 
Whole  blood (2-3 drops) 
Test-card with card reader 
Test cartridge with handheld 
analyser 
epoc BGEM™ 
i-STAT 
http://epocal.com 
https://www.abbottpointofcare.com 
Blood typing  Few minutes Fingerprick blood sample Disposable, credit card sized 
microfluidic device  
ABORhCard® http://www.micronics.net[155-
160][155-160][157-162] 
Cardiac Troponin-I assay 10 minutes Fingerprick blood sample Integrated, self-contained assay 
cartridge with handheld reader 
Nanōmix eLab http://nano.com 
Cancer diagnosis 100 minutes Plasma (1ml) Test cartdridge with platform Idylla™ ctBRAF 
Mutation assay 
https://www.biocartis.com 
Coagulation monitoring (Prothrombin 
Time test)  
3 minutes Whole blood (5µl) Memory microchip with a meter CoagMax® 
 
http://www.microvisk.com  
Fertility (FSH, LH, PL) 30 minutes Serum  (20µl) Test cartdridge with reader Acix 100 http://www.achiralabs.com 
Gastrointestinal infection (Clostridium Less than 2 hours Stool Test cartdridge with reader Verigene® C. http://www.nanosphere.us 
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difficile) difficile Test (CDF) 
HIV 50 minutes Whole blood or plasma 
(100µl) 
Test cartdridge with analyzer unit EOSCAPE-HIV 
 
http://www.wave80.com 
Inflammation (C-reactive protein) Few minutes Whole blood, serum or 
plasma (5µl) 
DVD-like disc with reading 
instrument 
spinit
®
 CRP 
 
http://biosurfit.com 
Lithium levels (bipolar disorder) Few minutes Fingerprick blood sample Disposable lab-chip with a meter Medimate MiniLab https://www.medimate.com 
Prostate Specific Antigen (PSA) 3 minutes Serum or plasma (30µl) Disposable cartridge with 
analyzing instrument 
FREND™ PSA plus http://nanoentek.com 
Septicaemia  2-3 hours Whole blood (10ml) USB size chip with purpose-
designed platform 
Genalysis
® 
 
http://www.dnae.com/index.html 
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